pharmaphorum

DECEMBER 14, 2022

But increased competition is on the horizon. Sodium oxybate — which in the late 1980s was marketed to bodybuilders and then became known as GHB and criminally used as a date rape drug — has been sold under the brand name Xyrem after gaining FDA approval in 2002. Competition starts to heat up. Classic treatment options.

Competition 116

Competition FDA Pharmaceutical Marketing 116

pharmaphorum

AUGUST 3, 2022

The US FDA has approved a new biosimilar of Roche and Novartis’ blockbuster ophthalmology therapy Lucentis – Coherus BioSciences’ Cimerli – which its developer claims is the first to be fully interchangeable with the originator product. The post Pressure rises on Lucentis, as Coherus biosimilar gets FDA nod appeared first on.

FDA 59

FDA Safety Sales Competition 59

Pharmaceutical Technology

MAY 19, 2023

Rituxan received its first FDA approval in 1997 for the treatment of B-cell non-Hodgkin’s lymphoma (B-NHL) and reached peak global sales of $7.5bn in 2014. Globally, the first rituximab biosimilar, Dr Reddy’s Laboratories’ Reditux, was approved in India in 2007. Rituxan’s success made it a prime target for biosimilar developers.

Sales 59

Sales Competition Marketing Patients 59

Evolve Your Success

MARCH 14, 2023

This is 2007. You are so spoiled if you are trying to get into this now because there’s competition in this space for you to reach that next level. They are probably going to have to live or move to three different cities, and that’s because it’s very competitive for them. Back then, I was the youngest person.

Doctors 246

Doctors Medical sales Sales Medical 246

PM360

NOVEMBER 21, 2024

Prior to becoming President of Global Human Health, he served as President of Merck’s global pharmaceutical business from 2007 to 2010. Food and Drug Administration (FDA) approval. You have to understand the marketplace around you…your competition, your blue space of where you can grow,” Adam said.

Ethics 59

Ethics Food and Drug Administration Marketing Leads 59

pharmaphorum

JANUARY 16, 2023

There were developments in the past 12 months, true – Biogen/Eisai’s lecanemab (now branded Leqembi) showed clear success in the Clarity AD trial and received approval by FDA on 6th January 2023. Difficile at the end of November 2022, but in 2023 they will be joined by Seres, which expects an FDA decision in April 2023 on its C.

FDA 98

FDA Healthcare Healthcare Medicine 98